Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 85th Scientific Sessions
– Hengrui to present six abstracts highlighting clinical progress of GLP-1/GIP dual receptor agonist HRS9531 (KAI-9531) and GLP-1 receptor agonist HRS-7535 (KAI-7535) in type 2 diabetes and obesity –
JIANGSU, China and BOSTON, June 16, 2025 (GLOBE NEWSWIRE) -- Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions, today announced the presentation of six abstracts at the 85th Scientific Sessions of the American Diabetes Association (ADA), taking place June 20-23, 2025, in Chicago, IL. The presentations will highlight the breadth of the companies' metabolic disease portfolio, including data from several clinical-stage injectable and oral therapies. Data presented will cover results from clinical trials sponsored and conducted by Hengrui for an injectable GLP-1/GIP receptor dual agonist HRS9531 (in development as KAI-9531 outside of Greater China), an oral small molecule GLP-1 receptor agonist HRS-7535 (KAI-7535), and an oral formulation of HRS9531 (KAI-9531).
The following abstracts were submitted by Hengrui and accepted for presentation:
HRS9531Oral presentation: Friday, June 20, 5:45-6:00 p.m. CT
Phase 2 clinical trial of HRS9531 in participants with type 2 diabetes up to 32 weeks
Abstract 126-OR: Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist in Participants with Type 2 Diabetes Mellitus Up to 32 Weeks
Posters: Sunday, June 22, 12:30-1:30 p.m. CT
Phase 1 clinical trial of HRS9531 (oral peptide) in healthy participants
Abstract 797-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 Tablet, an Oral Dual GLP-1/GIP Receptor Agonist, in Healthy Participants: A Phase 1 Study
Phase 2 clinical trial of HRS9531 in adults with obesity without diabetes up to 52 weeks
Abstract 853-P: Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist (HRS9531), in Obese Adults without Diabetes: Up to 52-Week Treatment
Phase 2 clinical trial of HRS9531 high dose (8 mg) in adults with obesity or overweight without diabetes
Abstract 874-P: Efficacy and Safety of a Novel Dual GLP-1/GLP Receptor Agonist in Chinese Overweight or Obese Adults without Diabetes
HRS-7535Posters: Sunday, June 22, 12:30-1:30 p.m. CT
Phase 2 clinical trial of HRS-7535 in adults with type 2 diabetes
Abstract 837-P: Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (HRS-7535) in Type 2 Diabetes Mellitus Patients Inadequately Controlled by Metformin
Phase 2 clinical trial of HRS-7535 in adults with obesity without diabetes
Abstract 865-P: Efficacy and Safety of a Novel Oral Small Molecule GLP-1RA in Chinese Obese Adults without Diabetes
All abstracts will be published online in the journal Diabetes® and presentations will be accessible on the Scientific Publications section of the Kailera website following the congress. Additional information can be found on the ADA website.
About Hengrui PharmaJiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. With a global R&D team that includes 14 R&D centers and more than 5,500 professionals, Hengrui Pharma's therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. To date, Hengrui has commercialized 23 new molecular entity drugs and 4 other innovative drugs in China. Founded in 1970 with the core principle of putting patients first, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology.
About Kailera TherapeuticsKailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera's most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that has demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera's mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health. The Company is based in Waltham, MA and San Diego, CA. For more information, visit www.kailera.com and follow us on LinkedIn and X.
Contact Information for Hengrui PharmaDGA Grouphengrui@dgagroup.com
Contact Information for KaileraMaura GavaghanVice President, Corporate Communications and Investor Relationsmaura.gavaghan@kailera.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Sizzle Acquisition Corp. II Completes $230,000,000 Initial Public Offering
NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Sizzle Acquisition Corp. II (the 'Company') announced today the completion of its initial public offering of 23,000,000 units at a price of $10.00 per unit, resulting in gross proceeds of $230,000,000. Sizzle The units began trading on the Nasdaq Global Market on April 2, 2025, under the ticker symbol 'SZZLU.' Each unit consists of one share of common stock and one right to receive one-tenth (1/10) of a share of common stock upon the consummation of an initial business combination. The common stock and Share Rights are expected to trade separately under the symbols 'SZZL' and 'SZZLR' once eligible. Sizzle Acquisition Corp. II is a blank check company formed for the purpose of effecting a business combination with one or more businesses across sectors including hospitality, restaurant, food and beverage, retail, consumer, real estate (including proptech), food-related technology, professional sports, and airlines. The Company is focused on identifying established, scalable businesses operating within or adjacent to these sectors in the United States and other developed markets. The Company is led by Steve Salis (Chief Executive Officer and Chairman), Jamie Karson (Non-Executive Vice Chairman), and Daniel Lee (Chief Financial Officer and Head of Business and Corporate Development). The Board of Directors includes Neil Leibman, Warren Thompson, and David Perlin. This is the second SPAC sponsored by Salis Holdings. The team's previous vehicle, Sizzle Acquisition Corp., completed a merger with European Lithium to form Critical Metals Corp. in early 2024. Cantor Fitzgerald & Co. acted as sole book-running manager for the offering. Media Contact: Sheena Lajoiesl@ Disclaimer: This press release is provided by the Sizzle Acquisition Corp. II. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing involves significant risks, including the potential loss of capital. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Legal Disclaimer: This media platform provides the content of this article on an "as-is" basis, without any warranties or representations of any kind, express or implied. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above. A photo accompanying this announcement is available at while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
The Hill
3 hours ago
- The Hill
Senate takes more flexible approach to GOP's green tax credit rollback
The Senate's version of the 'big beautiful bill' includes changes to green energy tax credits that are more flexible than those passed by the House — but would still be a significant rollback. This flexibility is likely to please moderates in both chambers who felt that the House version was too stringent. However, it could be teeing up a collision with the conservative House Freedom Caucus, whose board said it will 'not accept' Senate changes that 'water down' its major cutbacks to the climate-friendly credits. The Senate text appears to eliminate the most stringent provision in the House bill, deleting a measure that would have required climate-friendly energy sources to start construction within 60 days of the bill's enactment to qualify for the credits at all. Instead, things such as solar panels and wind farms would need to begin construction this year in order to receive the full credit amount. Projects that begin construction in 2026 would get 60 percent of the credit while projects that begin construction in 2027 receive 20 percent. Projects constructed in 2028 or later would not be eligible for the credit. This, too, appears to be more flexible than the House text, which required projects to not just start construction but actually be producing electricity by the end of 2028 to qualify for the credit. Nevertheless, the Senate provisions are still a major rollback of the tax credits passed by Democrats in their 2022 Inflation Reduction Act. Under that law, the credits would have lasted until either 2032 or when U.S. emissions from the electric sector are 25 percent lower than their 2022 levels, whichever came later. The Senate text also adds carve outs for hydropower, nuclear and geothermal, allowing them to receive the full credit if they begin construction before 2034. And it appears to loosen a provision in the House bill that barred the credits from applying to any energy project that contained Chinese components, subcomponents or minerals after this year. The upper chamber instead seeks to set thresholds for how much of the value of a component may come from China.
Miami Herald
3 hours ago
- Miami Herald
Trump's trade and tax policies start to stall U.S. battery boom
Battery manufacturing began to take off in the United States in recent years after Congress and the Biden administration offered the industry generous incentives. But that boom now appears to be stalling as the Trump administration and Republican lawmakers try to restrict China's access to the American market. From South Carolina to Washington state, companies are slowing construction or reconsidering big investments in factories for producing rechargeable batteries and the ingredients needed to make them. A big reason is that higher trade barriers between the United States and China are fracturing relationships between suppliers and customers in the two countries. At the same time, Republicans are seeking to block battery makers with ties to China, as well as those that rely on any Chinese technology or materials, from taking advantage of federal tax credits. The industry is also dealing with a softening market for electric vehicles, which Republicans and President Donald Trump have targeted. The China-related restrictions -- included in the version of Trump's domestic policy bill passed by the House -- would be very difficult for many companies to operate under. China is the world's top battery manufacturer and makes nearly all of certain components. The Trump policy bill highlights a difficult dilemma. The United States wants to create a homegrown battery industry and greatly reduce its dependence on China -- and many Republican lawmakers want to end it altogether. But China is already so dominant in this industry that it will be incredibly hard for the United States to become a meaningful player without working with Chinese companies. To cultivate a domestic industry, experts say, the United States needs to rely on foreign components and know-how as it builds its own supply chains and expertise, much as China did in the auto industry. Among the plants at risk is a $3 billion battery factory Ford Motor is building in Marshall, Michigan, which is set to start making battery cells next year for the company's electric cars. Ford is licensing technology from the Chinese battery giant Contemporary Amperex Technology Co., which would quickly make it ineligible for federal subsidies under the House bill. A loss of tax credits 'will imperil what we do in Marshall,' William Clay Ford Jr., the company's executive chair, said last month. 'We made a certain investment based upon a policy that was in place,' he added. 'It's not fair to change policies after all the expenditure has been made.' Some companies are already pulling back. This month, the battery maker AESC paused construction of a $1.6 billion electric-vehicle battery plant in South Carolina, citing 'policy and market uncertainty.' Batteries made there, which are meant to power BMW's electric vehicles, also would soon become ineligible for federal subsidies, at least in part because a Chinese company owns a large portion of AESC. Those tax credits amount to roughly $3,375 for the average electric vehicle battery, according to UBS. Across the country, a startup, Group14 Technologies, slowed construction of a battery materials factory in Moses Lake, Washington, after its customers in China balked at paying higher tariffs. Instead, the company is focusing on ramping up production in South Korea, said Rick Luebbe, Group14's CEO. 'What caught the attention of our customers, particularly in China, was the really aggressive back-and-forth where the tariffs went up over 100%,' Luebbe said. 'At that point, folks said, 'You know what, maybe we'll just hold off.'' Trump and his aides have said they want companies to manufacture more in the United States. They also want more U.S. mining of critical minerals, many of which form the building blocks of batteries. But they have criticized electric vehicles and wind and solar energy, which drive demand for batteries. Ben Dietderich, an Energy Department spokesperson, said the administration was investing in projects that would deliver a return on investment for Americans but did not directly address batteries. The administration 'is working to develop more secure supply chains for critical energy infrastructure,' Dietderich said. A White House spokesperson, Kush Desai, said the administration would 'shore up America's supply of critical minerals' by investigating imports of such materials on natural security grounds, mining for them offshore and repealing regulations. Domestic battery makers have other problems besides the U.S. posture toward China. Chief among them is that electric vehicles have not become as popular in the United States as many companies had expected. As a result, many companies delayed, canceled or scaled back projects, even before Trump increased tariffs and Republican lawmakers sought to eliminate tax credits. Companies canceled more than $6 billion in planned U.S. battery factories in the first quarter, according to Rhodium Group, a research firm that tracks investments with Massachusetts Institute of Technology's Center for Energy and Environmental Policy Research. The Republican policy bill would further erode demand for electric cars -- and, by extension, the batteries that power them -- by scrapping a $7,500 tax credit available to many people who buy or lease them. If that tax credit goes away, all planned U.S. battery plants will become unnecessary and more than two-thirds of existing capacity could shut down, according to an analysis by the Princeton University-led REPEAT Project. Jennifer Granholm, the energy secretary under President Joe Biden, said scrapping clean-energy incentives would cost jobs and undermine U.S. energy security by making the country more dependent on China. 'For there to be an effective industrial strategy, you have to make America irresistible for investment,' said Granholm, a former governor of Michigan. 'You can't play a game with no offense.' She said lawmakers should differentiate between Chinese equipment that could pose a threat to national security, such as devices that connect to the internet, and more basic materials like screws. Others say the United States should welcome foreign investment, including from China, and learn from it. 'Restricting our market is just a first-order bad idea,' said Ann E. Harrison, an economist and former dean of the business school at the University of California, Berkeley. Competition drives innovation and efficiency, without which companies often struggle to survive in the long term, she said. 'The Chinese are already so far ahead,' Harrison said. 'At this point, I don't see us making the leap without fewer constraints.' Group14, the startup, now expects to start production at its Washington state plant early next year, instead of this summer. The company makes a material that is designed to be a substitute for graphite, a key battery component that is almost entirely produced or processed in China. 'We can pull that back forward if there's resolution on tariff uncertainty and we see that wave of demand pick back up again,' Luebbe said. A spokesperson for AESC said the company planned to restart construction in South Carolina once the market stabilized. The company has already spent more than $1 billion developing the site. It also makes batteries for energy storage systems in Tennessee. BMW expects to start making electric vehicles nearby in late 2026, as planned, a spokesperson, Phil Dilanni, said. He declined to say where the batteries would come from. This article originally appeared in The New York Times. Copyright 2025
